BYSI - NASDAQ
BeyondSpring Inc.
$1.71
+4.9%BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
At a Glance
Live Snapshotbysi
Selling, General and Administrative Expenses
Last Annual Value
4.56M
3-Year CAGR
-30%
5-Year CAGR
-27%
10-Year CAGR
14%
BeyondSpring Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
BeyondSpring Inc. NASDAQ:BYSI | 4.56M | -15.3% | -31.7% | 9.0% | |
 Estrella Immunopharma, Inc. NASDAQ:ESLA | 2.81M | -4.2% | 56.9% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 311.90K | -81.5% | -61.1% | -25.2% | |
 Sutro Biopharma, Inc. NASDAQ:STRO | 41.02M | -13.1% | -6.0% | 10.7% | |
 MiNK Therapeutics, Inc. NASDAQ:INKT | 6.73B | 867.5% | 330.3% | N/A | |
 MediciNova, Inc. NASDAQ:MNOV | 6.16M | 5.5% | 1.5% | -1.8% | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 39938.23B | 11340.3% | 1890.9% | 323.4% | |
 CEL-SCI Corporation AMEX:CVM | 4.22M | -22.3% | -20.2% | -4.2% | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 21.15M | N/A | 15.0% | N/A | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 19.33M | -6.4% | 7.2% | N/A | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 23.85M | -5.7% | 0.4% | N/A |
BeyondSpring Inc. Fair Value Envelope
Related Guides
Continue your BYSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.